New molecular and cellular targets for chemoprevention and treatment of skin tumors by plant polyphenols: A critical review

Current Medicinal Chemistry

Volumn 20, Issue 7, 2013, Pages 852-868

  Korkina, L G ^a   Pastore, S ^a   Dellambra, E ^a   De Luca, C ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

AhR; Cellular senescence; EGFR; Epigenetics; Melanoma; Plant polyphenols; Skin cancers; Stem cells

Indexed keywords

ACTEOSIDE; ANTHOCYANIN; ANTINEOPLASTIC AGENT; CAPSAICIN; CATECHIN; CURCUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GENISTEIN; HYPERICIN; ISOFLAVONE; LEONTOPODIC ACID; PLANT GLYCOSIDE; POLYDANTIN; POLYPHENOL; POLYPHENOL DERIVATIVE; QUERCETIN; RESVERATROL; SILIBININ; SILYMARIN; STILBENE DERIVATIVE; TEUPOLIOSIDE; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL AGING; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL RENEWAL; CHEMOPROPHYLAXIS; DNA DAMAGE; G1 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; HUMAN; INFLAMMATION; KERATINOCYTE; NONHUMAN; OXIDATIVE STRESS; PHOTOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN TOXICITY; UPREGULATION;

EID: 84877995487     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320070002     Document Type: Review

References (243)

1. Aggarwal, B.B.; Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol., 2006 , 71(10), 1397-1421.
2. Katiyar, S.K. UV-induced immune suppression and photocarcinogenesis: chemoprevention by dietary botanical agents. Cancer Lett., 2007, 255(1), 1-11. (Pubitemid 47212603)
3. Afaq, F.; Katiyar, S.K. Polyphenols: skin photoprotection and inhibition of photocarcinogenesis. Mini Rev. Med. Chem., 2011, 11(14), 1200-1215.
4. Aziz, M.H.; Reagan-Shaw, S.; Wu, J.; Longley B.J.; Ahmad, N. Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease? FASEB J., 2005, 19(9), 1193-1195. (Pubitemid 40946462)
5. Korkina, L.G.; De Luca, C.; Kostyuk, V.A.; Pastore, S. Plant polyphenols and tumors: from mechanims to therapy, prevention, and protection against toxicity of anti-cancer treatments. Curr. Med. Chem., 2009, 16(30), 3943-3965.
6. Meeran, S. M.; Singh, T.; Nagy, T. R.; Katiyar, S. K., High-fat diet exacerbates inflammation and cell survival signals in the skin of ultraviolet Birradiated C57BL/6 mice. Toxicol Appl Pharmacol 2009, 241(3), 303-310.
7. Vanden Berghe, W.; Haegeman, G. Epigenetic remedies by dietary phytochemicals against inflammatory skin disorders: myth or reality? Curr. Drug Metab., 2010, 11(5), 436-450.
8. Sticozzi, C.; Belmonte, G.; Pecorelli, A.; Arezzini, B.; Gardi, C.; Maioli, E.; Miracco, C.; Toscano, M.; Forman, H.J.; Valacchi, G. Cigarette smoke affects keratinocytes SRB1 expression and localization via H2O2 production and HNE protein adducts formation. PLoS One, 2012, 7(3), e33592.
9. Siddens, L.K.; Larkin, A.; Krueger, S.K.; Bradfield, C.A.; Waters, K.M.; Tilton, S.C.; Pereira, C.B.; Lohr, C.V.; Arlt, V.M.; Phillips, D.H.; Williams, D.E.; Baird, W.M. Polycyclic aromatic hydrocarbons as skin carcinogens: comparison of benzo[a]pyrene, dibenzo[def.p]chrysene and three environmental mixtures in the FVB/N mice. Toxicol. Appl. Pharmacol., 2012, [Epub ahead of print 23 Aug], doi: 10.1016/j.taap.2012.08.014.
10. Balducci, L.; Ershler, W.B. Cancer and ageing: a nexus at several levels. Nat. Rev. Cancer, 2005, 5(8), 655-662. (Pubitemid 41081391)
11. Surh, Y. J., Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer, 2003, 3(10), 768-780.
12. Hermans, N.; Cos, P.; Maes, L.; De Bruyne, T.; Vanden Berghe, D.; Vlietnick, A.J.; Pieters, L. Challenges and pitfalls in antioxidant research. Curr. Med. Chem., 2007, 14(4), 417-430.
13. De la Lastra, C.A.; Villegas, I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem. Soc. Trans., 2007, 35(Pt5), 1156-1160. (Pubitemid 350206449)
14. Korkina, L.; Pastore, S.; De Luca, C.; Kostyuk, V. Metabolism of plant polyphenols in the skin: beneficial versus deleterious effects. Curr. Drug Metab., 2008, 9(8), 710-729.
15. Gopalacrishnan, A.; Kong, A.N.T. Anticarcinogenesis by dietary phytochemicals: cytoprotection by Nrf2 in normal cells and cytotoxicity by modulation of transcription factors NF-kB and AP-1 in abnormal cancer cells. Food Chem. Toxicol., 2008, 46(4), 1257-1270.
16. Hayes, J.D.; McMahon, M.; Chowdhry, S.; Dinkova-Kostova, A. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid. Redox Signal., 2010, 13(11), 1713-1748.
17. Lau, A.; Villeneuve N.F.; Sun, Z.; Wong, P.K.; Zhang, D.D. Dual roles of Nrf2 in cancer. Pharmacol. Res., 2008, 58(5-6), 262-270.
18. Kensler, T.W.; Wakabayashi, N. Nrf2: friend or foe for chemoprevention? Carcinogenesis, 2010, 31(1), 90-99.
19. Maher, J.; Yamamoto, M. The rise of antioxidant signaling -The evolution and hormetic actions of Nrf2. Toxicol. Appl. Pharmacol., 2010, 244(1), 4-15.
20. De Nicola, G.M.; Karreth, F.A.; Humpton, T.J.; Gopinathan, A.; Wei, C.; Frese, K.; Mangal, D.; Yu, K.H.; Yeo, C.J.; Calhoun, E.S.; Scrimieri, F.; Winter, J.M.; Hruban, R.H.; Iacobuzio-Donahue, C.; Kern, S.E.; Blair, I.A.; Tuveson, D.A. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature, 2011, 475(7354), 106-109.
21. Pastore, S.; Lulli, D.; Pascarella, A.; Maurelli, R.; Dellambra, E.; Potapovich, A.; Kostyuk, V.; De Luca, C.; Korkina, L. Resveratrol Enhances Solar UVInduced Responses in Normal Human Epidermal Keratinocytes. Photochem. Photobiol., 2012, doi: 10.1111/j.1751-1097.2012.01195.x.
22. Mercader, A.G.; Pomilio, A.B. (Iso)flav(an)ones, chalcones, catechins, and theaflavins as anticarcinogens: mechanisms, anti-multidrug resistance and QSAR studies. Curr. Med. Chem., 2012, 19(25), 4324-4347.
23. Ulrich, C.M., Bigler, J., Potter, J.D. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat. Rev. Cancer, 2006, 6(2), 130-140. (Pubitemid 43361545)
24. Bonafé, M.; Storci, G.; Franceschi, C. Inflamm-Aging of the stem cell niche: breast cancer as a paradigmatic example: breakdown of the multi-shell cytokine network fuels cancer in aged people. Bioessays, 2011, 34(1), 40-49.
25. Maund, S.L.; Cramer, S.D. The Tissue-Specific Stem Cell as a Target for Chemoprevention Stem Cell Rev., 2011, 7(2), 307-314.
26. Perez-Losada, J.; Balmain, A. Stem-cell hierarchy in skin cancer. Nat. Rev. Cancer, 2003, 3(6), 434-443. (Pubitemid 37328847)
27. Pratt, M.A.; Tibbo, E.; Robertson, S.J.; Jansson, D.; Hurst, K.; Perez-Iratxeta, C.; Lau, R.; Niu, M.Y. The canonical NF-kappaB pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population. Oncogene, 2009, 28(30), 2710-2722.
28. Storci, G.; Sansone, P.; Mari. S.; D'Uva, G.; Tavolari, S.; Guarnieri, T.; Taffurelli, M.; Ceccarelli, C.; Santini, D.; Chieco, P.; Marcu, K.B.; Bonafé, M. TNFalpha upregulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. J. Cell Physiol., 2010, 225(3),:682-691.
29. Iliopoulos, D.; Hirsch, H.A.; Wang, G.; Struhl, K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with nonstem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. USA, 2011, 108(4),1397-1402.
30. Coppé, J.P.; Desprez, P.Y.; Krtolica, A.; Campisi, J. The senescence associated secretory phenotype: the dark side of tumor suppression. Ann. Rev. Pathol., 2010, 5(2), 99-118.
31. Hei, T.K.; Zhou, H.; Chai, Y.; Ponnaiya, B.; Ivanov, V.N. Radiation induced nontargeted response: mechanism and potential clinical implications. Curr. Mol. Pharmacol., 2011, 4(2), 96-105.
32. Martin, O.A.; Redon, C.E.; Dickey, J.S.; Nakamura, A.J.; Bonner, W,M. Parainflammation mediates systemic DNA damage in response to tumor growth. Commun. Integr. Biol., 2011, 4(1), 78-81.
33. Rodier, F; Campisi, J. Four faces of cellular senescence. J. Cell Biol., 2011,192(4), 547-556.
34. Cabarcas, S.M.; Mathews, L.A.; Farrar W.L. The cancer stem cell niche-There goes the neighborhood? Int. J. Cancer, 2011, 129(10), 2315-2327.
35. Kuilman, T.; Michaloglou, C.; Vredeveld, L.C.; Douma, S.; van Doorn, R.; Desmet, C.J.; Aarden, L.A.; Mooi, W.J.; Peeper, D.S. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell, 2008, 133(6), 1019-1031. (Pubitemid 351787746)
36. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357(9255), 539-545. (Pubitemid 32173595)
37. Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature, 2002, 420(6917), 860-867. (Pubitemid 36019639)
38. Biswas SK; Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol., 2010, 11(10), 889-896.
39. Korkaya, H.; Liu, S.; Wicha, M.S. Regulation of cancer stem cells by cytokine networks: Attacking cancer's inflammatory roots. Clin. Cancer Res., 2011, 17(19), 6125-6129.
40. Jones, S.A.; Scheller, J.; Rose-John, S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest., 2011, 121(9), 3375-3383.
41. Blanpain, C.; Fuchs, E., Epidermal homeostasis: a balancing act of stem cells in the skin. Nat. Rev. Mol. Cell. Biol., 2009, 10(3), 207-217.
42. Bickford, P. C.; Tan, J.; Shytle, R. D.; Sanberg, C. D.; El-Badri, N.; Sanberg, P. R., Nutraceuticals synergistically promote proliferation of human stem cells. Stem Cells Dev., 2006, 15(1), 118-123.
43. Shytle, R. D.; Ehrhart, J.; Tan, J.; Vila, J.; Cole, M.; Sanberg, C. D.; Sanberg, P. R.; Bickford, P. C., Oxidative stress of neural, hematopoietic, and stem cells: protection by natural compounds. Rejuvenation Res., 2007, 10(2), 173-178. (Pubitemid 46944985)
44. Kawasaki, B. T.; Hurt, E. M.; Mistree, T.; Farrar, W. L., Targeting cancer stem cells with phytochemicals. Mol. Interv., 2008, 8(4), 174-184.
45. Crea, F.; Mathews, L. A.; Farrar, W. L.; Hurt, E. M., Targeting prostate cancer stem cells. Anticancer Agents Med. Chem., 2009, 9(10), 1105-1113.
46. Pahlke, G.; Ngiewih, Y.; Kern, M.; Jakobs, S.; Marko, D.; Eisenbrand, G. Impact of quercetin and EGCG on key elements of the Wnt pathway in human colon carcinoma cells. J Agric. Food Chem., 2006, 54(19), 7075-7082. (Pubitemid 44554923)
47. Kim, J.; Zhang, X.; Rieger-Christ, K.; Summerhayes, I.C.; Wazer, D.E.; Paulson, K.E.; Yee, A.S. Suppression of Wnt signaling by the green tea compound ()-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1. J. Biol. Chem., 2006, 281(16), 10865-10875. (Pubitemid 43855509)
48. Slusarz , A.; Shenouda, N.; Sakla, M. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res., 2010, 70(8), 3382-3390.
49. Hayflick, L.; Moorhead, P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res., 1961, 25(3), 585-621.
50. Kong, Y.; Cui, H.; Ramkumar, C.; Zhang, H. Regulation of Senescence in Cancer and Aging. J. Aging Res., 2011, 1-14.
51. Ben-Porath, I.; Weinberg, R.A. The signals and pathways activating cellular senescence. Inter. J. Biochem. Cell Biol., 2005, 37(5), 961-976. (Pubitemid 40311739)
52. Blackburn, E.H. Switching and signaling at the telomere. Cell, 2001, 106 (6), 661-673. (Pubitemid 32900658)
53. Martens, U.M.; Chavez, E. A.; Poon, S.S.S.; Schmoor, C.; Lansdorp, P.M. Accumulation of short telomeres in human fibroblasts prior to replicative senescence. Exper. Cell Res., 2000, 256(1), 291-299. (Pubitemid 30211191)
54. Bodnar, A.G.; Ouellette, M.; Frolkis, M.; Holt, S.E.; Chiu, C.P.; Morin, G.B.; Harley, C.B.; Shay, J.W.; Lichtsteiner, S.; Wright, W.E. Extension of life-span by introduction of telomerase into normal human cells. Science, 1998, 279(5349), 349-352. (Pubitemid 28063364)
55. Kiyono, T.; Foster, S.A.; Koop, J.I.; McDougall, J.K.; Galloway, D.A.; Klingelhutz, A.J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature, 1998, 396(6706), 84-88. (Pubitemid 28520454)
56. Hahn, W.C.; Stewart, S. A.; Brooks, M.W.; York, S.G.; Eaton, E.; Kurachi, A.; Beijersbergen, R.L.; Knoll, J.H.; Meyerson, M.; Weinberg, R.A. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med., 1999, 5(10), 1164-1170. (Pubitemid 29474421)
57. Dimri, G.P. What has senescence got to do with cancer? Cancer Cell, 2005, 7(6), 505-512. (Pubitemid 40799244)
58. Hahn, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70. (Pubitemid 30046295)
59. Serrano, M.; Lin, A.W.; McCurrach, M.E.; Beach, D.; Lowe, S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell, 1997, 88(5), 593-602. (Pubitemid 27152402)
60. Shay, J.W.; Bacchetti, S. A survey of telomerase activity in human cancer. Eur. J. Cancer Part A, 1997, 33(5), 787-791.
61. Muntoni, A.; Reddel, R.R. The first molecular details of ALT in human tumor cells. Human Mol. Gen., 2005, 14(2), 191-196.
62. Feldser, D.M;. Greider, C.W. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell, 2007, 11(5), 461-469. (Pubitemid 46670077)
63. Cosme-Blanco, W.; Shen, M. F.; Lazar, A. J. F.; Pathak, S.; Lozano, G.; Multani, A.S.; Chang S. Telomere dysfunction suppresses spontaneous tu morigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep., 2007, 8(5), 497-503. (Pubitemid 46696521)
64. Schmitt, C.A.; Fridman, J.S., Yang, M.; Lee, S.; Baranov, E.; Hoffman, R.M.; Lowe, S.W. A senescence program controlled by p53 and p16 contributes to the outcome of cancer therapy. Cell, 2002, 109(3), 335-346. (Pubitemid 34606876)
65. Ventura, A.; Kirsch, D.G.; McLaughlin, M.E.; Tuveson, D.A.; Grimm, J.; Lintault, L.; Newman, J.; Reczek, E.E.; Weissleder, R.; Jacks, T. Restoration of p53 function leads to tumor regression in vivo. Nature, 2007, 445(7128), 661-665. (Pubitemid 46232887)
66. Xue, W.; Zender, L.; Miething, C.; Dickins, R.A.; Hernando, E.; Krizhanovsky, V.; Cordon-Cardo, C.; Lowe, S.W. Senescence and tumor clearance is triggered by p53 restoration in murine liver carcinomas. Nature, 2007, 445(7128), 656-660. (Pubitemid 46232886)
67. Rodier, F.; Campisi, J. Four faces of cellular senescence. J. Cell Biol., 2011, 192(4), 547-556.
68. Wu, C.H.; van Riggelen, J.; Yetil A.; Fan, A.C.; Bachireddy, P.; Felsher, D.W. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl. Acad. Sci. USA., 2007, 104(32), 13028-13033. (Pubitemid 351737587)
69. Roninson, I.B. Tumor senescence as a determinant of drug response in vivo. Drug Resist. Updates, 2002, 5(5), 204-208. (Pubitemid 35429450)
70. Krtolica, A.; Parrinello, S.; Lockett, S.; Desprez, P.Y.; Campisi, J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. USA, 2001, 98(21), 12072-12077. (Pubitemid 32959828)
71. Coppe, J.P.; Patil, C.K.; Rodier, F.; Krtolica, A.; Beausejour, C.M.; Parrinello, S.; Hodgson, J.G.; Chin, K.; Desprez, P.Y.; Campisi, J. A human-like senescence-Associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS One., 2010, 5(2), e9188.
72. Rauser, C.L.; Mueller, L.D.; Rose, M.R. The evolution of late life. Ageing Res. Rev., 2006, 5(1), 14-32. (Pubitemid 43139665)
73. Queen, B.L.; Tollefsbol, T.O. Polyphenols and Aging. Curr Aging Sci., 2010, 3(1), 34-42.
74. Munro, J.; Barr, N.; Ireland, H.; Morrison, V.; Parkinson, E. Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock. Exper. Cell Res., 2004, 259(2), 525-538. (Pubitemid 38490504)
75. Balcerczyk, A.; Pirola L. Therapeutic potential of activators and inhibitors of sirtuins. Biofactors, 2010, 36(5), 383-393.
76. Kyrylenko, S.; Baniahmad, A. Sirtuin family: a link to metabolic signaling and senescence. Curr. Med. Chem., 2010, 17(26), 2921-2932.
77. Vanhaecke, T.; Papeleu, P.; Elaut, G.; Rogiers, V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr. Med. Chem., 2004, 11(2), 1629-1643. (Pubitemid 38735799)
78. Chung, S.; Yao, H.; Caito, S.; Hwang, J.; Arunachalam, H.; Rahman, I. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch. Biochem. Biophys., 2010, 501(1), 79-90.
79. Hofseth, L.J.; Singh, U.P.; Singh, N.P.; Nagarkatti, M.; Nagarkatti, P.S. Taming the beast within: resveratrol suppresses colitis and prevents colon cancer. Aging (Albany NY), 2010, 2(4), 183-184.
80. Lulli, D.; Potapovich, A.; Maurelli, R.; Dellambra, E.; Pressi, G.; Kostyuk, V.; Dal Toso, R.; De Luca, C.; Pastore, S.; Korkina, L. Anti-inflammatory effects of concentrated ethanol extracts of Edelweiss (Leontopodium alpinum Cass.) callus cultures towards human keratinocytes and endothelial cells. Mediators Inflamm., 2012, article ID 498393, doi: 10.1155/2012/498373.
81. Kaeberlein, M.; McDonagh, T.; Heltweg, B.; Hixon, J.; Westman, E.A.; Caldwell, S.D.; Napper, A.; Curtis, R.; DiStefano, P.S.; Fields, S.; Bedalov A.; Kennedy, B.K. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem., 2005, 280(17), 17038-17045. (Pubitemid 41389166)
82. Yarden, Y.; Sliwkowski, M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol., 2001, 2(2), 127-137. (Pubitemid 33674041)
83. Schneider, M.R.; Werner, S.; Paus, R.; Wolf, E. Beyond wavy hairs. The epidermal growth factor receptor and its ligands in skin biology and pathology. Am. J. Pathol., 2008, 173(1), 14-24. (Pubitemid 351947951)
84. Pastore, S.; Mascia, F.; Mariani, V.; Girolomoni, G. The epidermal growth factor receptor system in skin repair and inflammation. J. Invest. Dermatol., 2008, 128(6), 1365-1374. (Pubitemid 351693180)
85. Wetzker, R.; Böhmer, F.D. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat. Rev. Mol. Cell. Biol., 2003, 4(8), 651-657. (Pubitemid 36934967)
86. Canguilhem, B.; Pradines, A.; Baudouin, C.; Boby, C.; Lajoie-Mazenc, I.; Charveron, M.; Favre, G. RhoB protects human keratinocytes from UVBinduced apoptosis through epidermal growth factor receptor signaling. J. Biol. Chem., 2005, 280(52), 43257-43263. (Pubitemid 43049292)
87. Li, T.; Perez-Soler, R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol., 2009, 4(2), 107-119.
88. Dominey, A.M.; Wang, H.J.; King, L.; Nanney, L.B.; Gagne, T.A.; Sellheyer, K.; Bundman, D.S.; Longley, M.A.; Rothnagel, J.A.; Greenhalgh, D.A. Targeted overexpression of transforming growth factor alpha in the epidermis of transgenic mice elicits hyperplasia, hyperkeratosis, and spontaneous, squamous papillomas. Cell Growth Differ., 1993, 4(12), 1071-1082.
89. Vassar, R.; Hutton, M.E.; Fuch, E. Transgenic overexpression of TGF-bypasses the need for c-Ha-ras mutations in mouse skin tumorigenesis. Mol. Cell. Biol., 1992, 12(10), 4643-4653.
90. Dlugosz, A.A.; Hansen, L.; Cheng, C.; Alexander, N.; Denning, M.F.; Threadgill, D.W.; Magnuson, T.; Coffey, R.J.; Yuspa, S.H. Targeted disruption of the epidermal growth factor receptor impairs growth of squamous papillomas expressing the v-ras(Ha) ondogene but does not block in vitro keratinocyte responses to oncogenic ras. Cancer Res., 1997, 57(15), 3180-3188. (Pubitemid 27351733)
91. Hansen, L.A.; Woodson, R.L.; Holbus, S.; Strain, K.; Lo, Y.C.; Yuspa, S.H. The epidermal growth factor receptor is required to maintain the proliferative population in the basal compartment of epidermal tumors. Cancer Res., 2000, 60(13), 3328-3332. (Pubitemid 30482140)
92. Casanova, M.L.; Larcher, F.; Casanova, B.; Murillas, R.; Fernandez-Acenero, M.J.; Villanueva, C.; Martinez-Palacio, J.; Ullrich, A.; Conti, C.J.; Torcano, J.L. A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res., 2002, 62(12), 3402-3407. (Pubitemid 34651386)
93. El-Abaseri, T.B.; Fuhrman, J.; Trempus, C.; Shendrik, I.; Tennant, T.W.; Hansen, L.A. Chemoprevention of UV-light-induced skin tumorigenesis by inhibition of the epidermal growth factor receptor. Cancer Res., 2005, 65(9), 3958-3965. (Pubitemid 40616379)
94. Mendelsohn, J.; Baselga, J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol., 2006, 33(4), 369-385. (Pubitemid 44142736)
95. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; Louis, D.N.; Christiani, D.C.; Settleman, J.; Haber, D.A. Activating mutations in the epidermal growth facto receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2004, 350(21), 2129-2139. (Pubitemid 38637993)
96. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Gruelich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M.J.; Sellers, W.R.; Johnson, B.E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical responseto gefitinib therapy. Science, 2004, 304(5676), 1597-1600.
97. Willmore-Payne, C.; Holden, J.A.; Layfield, L.J. Detection of EGFR-And HER2-Activating mutations in squamous cell carcinoma involving the head and neck. Mol. Pathol., 2006, 19(9), 634-640.
98. Fogarty, G.B.; Conus, N.M.; Chu, J.; McArthur, G. Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. Br. J. Dermatol., 2007, 156(1), 92-98. (Pubitemid 44924151)
99. Shimizu, T.; Izumi, H.; Oga, A.; Furumoto, H.; Murakami, T.; Ofuji, R.; Muto, M.; Sasaki, K. Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous cell of the skin. Dermatology, 2001, 202(3), 203-206. (Pubitemid 32506966)
100. Kondapalli, L.; Soltani, K.; Lacouture, M.E. The promise of moleculartargeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. J. Am. Acad. Dermatol., 2005, 53(2), 291-302. (Pubitemid 40979587)
101. Bae, Y.S.; Kang, S.W.; Seo, M.S.; Baines, I.C.; Tekle, E.; Chok, P.B.; Rhee, S.G. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. J. Biol. Chem., 1997, 272(1), 217-221.
102. Goldman, R.; Moshonov, S.; Chen, X.; Berchansky, A.; Furstenberger, G.; Zor, U. Crosstalk between elevation of intracellular [Ca2+], reactive oxygen species and phospholipase A2 stimulation in a human keratinocyte cell line Adv. Exp. Med. Biol., 1997, 433(1), 41-45.
103. Xu, Y.; Grachtchouk, V.; Voorhees, J.J.; Fisher, G.J. Receptor-Type proteintyrosine phosphatase-regulates epidermal growth factor receptor function. J. Biol. Chem., 2005, 280(52), 42694-42700. (Pubitemid 43049228)
104. Zhang, Z.Y. Functional studies of protein tyrosine phosphatases with chemical approaches. Biochim. Biophys. Acta, 2005, 1754(1-2), 100-107.
105. Bhattacharya, S.; LaButti, J.N.; Seiner, D.R.; Gates, K.S. Oxidative inactivation of protein tyrosine phosphatise 1B by organic hydroperoxides. Bioorg. Med. Chem. Lett., 2008, 18(22), 5856-5859.
106. Xu, Y.; Shao, Y.; Voorhees, J.J.; Fisher, G.J. Oxidative inhibition of receptor-Type proteine-Tyrosine phosphatase by ultraviolet irradiation activates epidermal growth factor receptor in human keratinocytes. J. Biol. Chem., 2006, 281(37), 27389-27397. (Pubitemid 44401766)
107. El-Abaseri, T.B.; Putta, S.; Hansen, L.A. Ultraviolet irradiation induces keratinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor. Carcinogenesis, 2006, 27(2), 225-231. (Pubitemid 43159873)
108. Mascia, F.; Mariani, V.; Girolomoni, G.; Pastore, S. Blockade of EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am. J. Pathol., 2003, 163(1), 303-312. (Pubitemid 36759615)
109. Sørensen, O.E.; Cowland, J.B.; Theilgaard-Mönch, K.; Liu, L.; Ganz, T.; Borregaard, N. Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J. Immunol., 2003, 170(11), 5583-5589. (Pubitemid 36617848)
110. Sørensen, O.E.; Thapa, D.R.; Roupé, M.; Valore, E.V.; Sjöbring, U.; Roberts, A.A.; Schmidtchen, A.; Ganz, T. Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor. J. Clin. Invest., 2006, 116(7), 1878-1885. (Pubitemid 44033312)
111. Pastore, S.; Mascia, F.; Mariotti, F.; Dattilo, C.; Mariani, V.; Girolomoni, G. ERK1/2 regulates epidermal chemokine expression and skin inflammation. J. Immunol., 2005, 174(8), 5047-5056.
112. Pivarcsi, A.; Müller, A.; Hippe, A.; Rieker, J.; van Lierop, A.; Steinhoff, M.; Seeliger, S.; Kubitza, R.; Pippirs, U.; Meller, S.; Gerber, P.A.; Liersch, R.; Buenemann, E.; Sonkoly, E.; Wiesner, U.; Hoffmann, T.K.; Schneider, L.; Piekorz, R.; Enderlein, E.; Reifenberger, J.; Rohr, U.P.; Haas, R.; Boukamp, P.; Haase, I.; Nürnberg, B.; Ruzicka, T.; Zlotnik, A.; Homey, B. Tumor immune escape by the loss of homeostatic chemokine expression. Proc. Natl. Acad. Sci. U.S.A., 2007, 104(48), 19055-19060.
113. Balagula, Y.; Garbe, C.; Myskowski, P.L.; Hauschild, A.; Rapoport, B.L.; Boers-Doets, C.B.; Lacouture, M.E. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int. J. Dermatol., 2011, 50(2), 129-146.
114. Potthoff, K.; Hofheinz, R.; Hassel, J.C.; Volkenandt, M.; Lordick, F.; Hartmann, J.T.; Karthaus, M.; Riess, H.; Lipp, H.P.; Hauschild, A.; Trarbach, T.; Wollenberg, A. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann. Oncol., 2011, 22(3), 524-535.
115. Lacouture, M.E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer., 2006; 6(10), 803-812. (Pubitemid 44450468)
116. Teillet, F.; Boumendjel, A.; Boutonnat, J.; Ronot, X. Flavonoids as RTK inhibitors and potential anticancer agents. Med. Res. Rev., 2008, 28(5), 715-745.
117. Ye, M.X.; Li, Y.; Yin, H.; Zhang, J. Curcumin: updated molecular mechanisms and intervention targets in human lung cancer. Int. J. Mol. Sci., 2012, 13(3), 3959-3978.
118. Lin, S.S.; Laai, K.C.; Hsu, S.C.; Yang, J.S.; Kuo, C.L.; Lin, J.P.; Ma, Y.S.; Wu, C.C.; Chung, J.G. Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and 9 and Vascular Endothelial Growth Factor (VEGF) Cancer Lett., 2009, 285(1), 127-133.
119. Hwang, Y.P.; Yun, H.J.; Choi, J.H.; Han, E.H.; Kim, H.G.; Song, G.Y.; Kwon, K.I.; Jeong, T,C.; Jeong, H.G. Suppression of EGF-induced tumor cell migration and matrix metalloproteinase-9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling. Mol. Nutr. Food Res., 2011, 55(4), 594-605.
120. Zitvogel, L.; Kepp, O.; Galluzzi, L.; Kroemer, G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol., 2012, 13(4), 343-351.
121. Kumar, G.; Dange, P.; Kailaje, V.; Vaidya, M.M.; Ramchandani, A.G.; Maru, G.B. Polymeric black tea polyphenols modulate the localization and activity of 12-O-Tetradecanoyl phorbol-13-Acetate-mediated kinases in mouse skin: Mechanisms of their anti-Tumor-promoting action. Free Radic. Biol. Med., 2012, 53(6), 1358-1370.
122. Korkina, L.; Kostyuk, V.; De Luca, C.; Pastore, S. Plant phenylpropanoids as emerging anti-inflammatory agents. Mini Rev. Med. Chem., 2011, 11(10), 823-835.
123. Albanesi, C.; Pastore, S. Pathobiology of chronic inflammatory skin diseases: interplay between keratinocytes and immune cells as a target for antiinflammatory drugs. Curr. Drug Metab., 2010, 11(3), 210-227.
124. Korkina, L.G.; Mikhal'chik, E.; Suprun, M.V.; Pastore, S.; Dal Toso, R. Molecular mechanisms underlying wound healing and anti-inflammatory properties of naturally occurring biotechnologically produced phenylpropanoid glycosides. Cell. Mol. Biol. (Noisy-le-grand), 2007, 53(5), 84-91. (Pubitemid 350164309)
125. Potapovich, A.I.; Lulli, D.; Fidanza, P.; Kostyuk, V.A.; De Luca, C.; Pastore, S.; Korkina, L.G. Plant polyphenols differentially modulate inflammatory responses of human keratinocytes by interfering with activation of transcription factors NFB and AhR and EGFR-ERK pathway. Toxicol. Appl. Pharmacol., 2011, 255(2), 138-149.
126. Pastore, S.; Lulli, D.; Fidanza, P.; Potapovich, A.I.; Kostyuk, V.A.; De Luca, C.; Mikhal'chik, E.; Korkina, L.G.. 2012. Plant polyphenols regulate chemokine expression and tissue repair in human keratinocytes through interaction with cytoplasmic and nuclear components of epidermal growth factor receptor system. Antioxid. Redox Signal., 2012, 16(4), 314-328.
127. Pastore, S.; Lulli, D.; Potapovich, A.I.; Fidanza, P.; Kostyuk, V.A.; Dellambra, E.; De Luca, C.; Maurelli, R.; Korkina, L.G. Differential modulation of stress-inflammation responses by plant polyphenols in cultured normal human keratinocytes and immortalized HaCaT cells. J. Dermatol. Sci., 2011, 63(2), 104-114.
128. Tergaonkar, V. NF-kappaB pathway: a good signaling paradigm and therapeutic target. Int. J. Biochem. Cell Biol., 2006, 38(10), 1647-1653. (Pubitemid 43947652)
129. Pavek, P.; Dvorak, Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr. Drug Metab., 2008, 9(2), 129-143. (Pubitemid 351461002)
130. Niestroy, J.; Barbara, A.; Herbst, K.; Rode, S.; van Liempt, M.; Roos, P.H. Single and concerted effects of benzo[a]pyrene and flavonoids on the AhR and Nrf2-pathway in the human colon carcinoma cell line Caco-2. Toxicol. In Vitro, 2011, 25(3), 671-683.
131. Swanson, H.I. Cytochrome P450 expression in human keratinocytes: an aryl hydrocarbon receptor perspective. Chem. Biol. Interact., 2004, 149(2-3), 69-79. (Pubitemid 39387210)
132. Rannug, A.; Fritsche, E. The aryl hydrocarbon receptor and light. Biol. Chem., 2006, 387(9), 1149-1157. (Pubitemid 44402061)
133. Katiyar, S.K.; Matsui, M.S.; Mukhtar, H. Ultraviolet-B exposure of human skin induces cytochromes P450 1A1 and 1B1. J. Invest. Dermatol., 2000, 114(2), 328-333. (Pubitemid 30417769)
134. Wincent, E.; Amini, N.; Luecke, S.; Glatt, H.; Bergman, J.; Crescenzi, C.; Rannug, A.; Rannug, U. The suggested physiologic aryl hydrocarbon receptor activator and cytochrome P450I substrate 6-formylindolo[3,2-b]carbazole is present in humans. J. Biol. Chem., 2009, 284(5), 2690-2696.
135. Nguyen, L.P.; Bradfield, C.A. The search for endogenous activators of aryl hydrocarbon receptor. Chem. Res. Toxicol., 2008, 21(1), 102-116. (Pubitemid 351219712)
136. Stejskalova, L.; Dvorak, Z.; Pavek, P. Endogenous and exogenous ligands of aryl hydrocarbon receptor: current state of art. Curr. Drug Metab., 2011, 12(2), 198-212.
137. Kostyuk, V.; Potapovich, A.; Stancato, A.; De Luca, C.; Lulli, D.; Pastore, S.; Korkina, L. Photo-oxidation products of skin surface squalene mediate metabolic and inflammatory responses to solar UV in human keratinocytes. PLoS One, 2012, 7(8), e44472.
138. Kalmes, M.; Hennen, J.; Clemens, J.; Blomeke, B. Impact of aryl hydrocarbon receptor (AhR) knockdown on cell cycle prograssion in human HaCaT keratinocytes. Biol. Chem., 2011, 392(7), 643-651.
139. Wu, D.; Wong, P.; Li, W.; Vogel, C.F.; Matsumura, F. Suppression of WIF-1 through promoter hypermethylation causes accelerated proliferation of the aryl hydrocarbon receptor (AHR) overexpressing MCF10AT1 breast cancer cells. Toxicology, 2011, 285(3), 97-103.
140. Hsieh, T.H.; Tsai, C.F.; Hsu, C.Y.; Kuo, P.L.; Chai, C.Y.; Wang, S.C.; Tsai, E.M. Phtalates induce proliferation and invasiveness of estrogen receptornegative breast cancer through the AhR/HDAC6/c-Myc signaling pathway. FASEB J., 2012, 26(2), 778-787.
141. Labrecque, M.P.; Takhar, M.K.; Hollingshead, B.D.; Prefontaine, G.G.; Perdew, G.H.; Beischlag, T.V. Dintinct roles for aryl hydrocarbon receptor nuclear translocator and ah receptor in estrogen-mediated signaling in human cancer cell lines. PLoS One, 2012, 7(1), e29545.
142. Dever, D.P.; Opanashuk, L.A. The aryl hydrocarbon receptor (AhR) contributes to the proliferation of human medulloblastoma cells. Mol. Pharmacol., 2012, 81(5), 669-678.
143. Shimamoto, K.; Dewa, Y.; Ishii, Y.; Kemmochi, S.; Taniai, E.; Hayashi, H.; Imaoka, M.; Morita, R.; Kuwata, K.; Suzuki, K.; Shibutani, M.; Mitsumori, K. Indole-3-carbinol enhances oxidative stress responses resulting in the induction of preneoplastic liver cell lesions in partially hepatectomized rats initiated with diethylnitrosamine. Toxicology, 2011, 283(2-3), 109-117.
144. Brooks, J.; Eltom, S.E. Malignant transformation of mammary epithelial cells by ectopic overexpression of the aryl hydrocarbon receptor. Curr. Cancer Drug Targets, 2011, 11(5), 654-669.
145. Tiong, C.T.; Chen, C.; Zhang, S.J.; Li, J.; Soshilov, A.; Denison, M.S.; Lee, L.S.; Tam, V.H.; Wong, S.P.; Xu, H.E.; Yong, E.L. A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ERprotein. Carcinogenesis, 2012, 33(5), 1089-1097.
146. Enjuanes, A.; Fernandez, V.; Hernandez, L.; Navarro, A.; Bea, S.; Pinyol, M.; Lopez-Guillermo, A.; Rosenwald, A.; Ott, G.; Campo, E.; Jares, P. Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma. PLoS ONE, 2011, 6(5), e19736.
147. Spink, B.C.; Bennett, J.A.; Lostritto, N.; Cole, J.R.; Spink, D.C. Expression of the aryl hydrocarbon receptor is not required for the proliferation, migration, invasion, or estrogen-dependent tumorigenesis of MCF-7 breast cancer cells. Mol. Carcinog., 2012, doi: 10.1002/mc.21889.
148. Wang, T.; Wyrick, K.L.; Meadows, G.G.; Wills, T.B.; Vorderstrasse, B.A. Activation of the aryl hydrocarbon receptor by TCDD inhibits mammary tumor metastasis in a syngeneic mouse model of breast cancer. Toxicol. Sci., 2011, 124(2), 291-298.
149. Mukai, R.; Shirai, Y.; Saito, N.; Fukuda, I.; Nishiumi, S.; Yoshida, K.; Ashida, H. Suppression mechanisms of flavonoids on aryl hydrocarbon receptormediated signal transduction. Arch. Biochem. Biophys., 2010, 501(1), 134-141.
150. Androutsopoulos, V.P.; Papakyriakou, A.; Vourloumis, D.; Tsatsakis, A.M.; Spandidos, D.A. Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacol. Ther., 2010, 126(1), 9-20.
151. Androutsopoulos, V.P.; Ruparelia, .KC.; Papakyriakou, A.; Filippakis, H.; Tsatsakis, A.M.; Spandidos, D.A. Anticancer effects of the metabolic products of the resveratrol analogue, DMU-212: structural requirements for potency. Eur. J. Med. Chem., 2011, 46(6), 2586-2595.
152. Ciolino, H.P.; Daschner, P.J.; Yeh, G.C. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res., 1998, 58(24), 5707-5712. (Pubitemid 29006410)
153. Beedanagari, S.R.; Bebenek, I.; Bui, P.; Hankinson, O. Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes. Toxicol. Sci., 2009, 110(1), 61-67.
154. Ciolino, H.P.; Daschner, P.J.; Yeh, G.C. Dietary flavonols quercetin and kaemferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem. J., 1999, 340(3), 715-722. (Pubitemid 29312869)
155. Rajaraman, G.; Yang, G.; Chen, J.; Chang, T.K.H. Modulation of CYP1B1 and CYP1A1 gene expression and activation of aryl hydrocarbon receptor by Ginkgo biloba extract in MCF-10A human mammary epithelial cells. Can. J. Physiol. Pharmacol., 2009, 87(9), 674-683.
156. Puppala, D.; Gairola, C.G.; Swanson, H.I. Identification of kaemferol as an inhibitor of cigarette smoke-induced activation of the aryl hydrocarbon receptor and cell transformation. Carcinogenesis, 2007, 28(3), 639-647. (Pubitemid 46523359)
157. Roebuck, K.A. Regulation of interleukin-8 gene expression. J. Interferon Cytokine Res., 1999, 19(5), 429-438. (Pubitemid 29269932)
158. Tauchi, M.; Hida, A.; Negishi, T.; Katsuoka, F.; Noda, S.; Mimura, J.; Hosoya, T.; Yanaka, A.; Aburatani, H.; Fujii-Kuriyama, Y.; Motohashi, H.; Yamamoto, M. Constitutive expression of aryl hydrocarbon receptor in keratinocytes causes inflammatory skin lesions. Mol. Cell. Biol., 2005, 2(1), 9360-9368. (Pubitemid 41507837)
159. Ikuta, T.; Namiki, T.; Fujii-Kuriyama, Y.; Kawajiri, K. AhR protein trafficking and function in the skin. Biochem. Pharmacol., 2009, 77(4), 588-596.
160. Haarmann-Stemmann, T.; Both, H.; Abel, J. Growth factors, cytokines and their receptors as downstream targets of arylhydrocarbon receptor (AhR) signaling pathways. Biochem. Pharmacol., 2009, 77(4), 508-520.
161. Luecke, S.; Backlund, M.; Jux, B.; Esser, C.; Krutmann J.; Rannug, A. The aryl hydrocarbon receptor (AHR), a novel regulator of human melanogenesis. Pigment Cell Melanoma Res., 2010, 23(6), 828-833.
162. Martinez-Carpio, P.A.; Trelles, M.A. Cutaneous epidermal growth factor receptor system following ultraviolet irradiation: exploring the role of molecular mechanisms. Photodermatol. Photoimmunol. Photomed., 2010, 26(5), 250-256.
163. Kalthoff, S.; Ehmer, U.; Freiberg, N.; Manns, M.P.; Strassburg, C.P. Interaction between oxidative stress sensor Nrf2 and xenobiotic-Activated aryl hydrocarbon receptor in the regulation of the human phase II detoxifying UDPglucuronosyltransferase 1A10. J. Biol. Chem., 2010, 285(9), 5993-6002.
164. Puga, A.; Ma, C.; Marlowe, J.L. The aryl hydrocarbon receptor cross-Talks with multiple signal transduction pathways. Biochem. Pharmacol., 2009, 77(4), 13-22.
165. Ohtake, F.; Baba, A.; Takada, I.; Okada, M.; Iwasaki, K.; Miki, H.; Takahashi, S.; Kouzmenko, A.; Nohara, K.; Chiba, T.; Fujii-Kuriyama, Y.; Kato, S. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature, 2007, 446(7135), 562-566. (Pubitemid 46514731)
166. Wang, Y.; Liang, Y.; Lu, Q. Micro RNA epigenetic alterations: predicting biomarkers and therapeutic targets in human diseases. Clin. Genet., 2008, 74(4), 307-315.
167. Vanden Berghe, W. Epigenetic impact of dietary polyphenols in cancer chemoprevention: lifelong remodeling of our epigenomes. Pharmacol. Res., 2012, 65(6), 565-576.
168. Szarc vel Szic, K.; Ndlovu, M.N.; Haegeman, G.; Vanden Berghe, W. Nature or nurture: let food be your epigenetic medicine in chronic inflammatory disorders. Biochem. Pharmacol., 2010, 80(12), 1816-1832.
169. Hardy, T.M.; Tollefsbol, T.O. Epigenetic diet: impact on the epigenome and cancer. Epigenomics, 2011, 3(4), 503-518.
170. Millington, G. W. Epigenetics and dermatological disease. Pharmacogenomics, 2008, 9(12), 1835-1850.
171. Howell, P. M., Jr.; Liu, S.; Ren, S.; Behlen, C.; Fodstad, O.; Riker, A. I. Epigenetics in human melanoma. Cancer Control, 2009, 16(3), 200-218.
172. Sigalotti, L.; Covre, A.; Fratta, E.; Parisi, G.; Colizzi, F.; Rizzo, A.; Danielli, R.; Nicolay, J.H.; Coral, S.; Maio, M. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J. Transl. Med., 2010, 8, 56, doi: 10.1186/1479-5876-8-56.
173. Lafon-Hughes, L.; Di Tomaso, M.V.; Mendez-Acuna, L.; Martinez-Lopez, W. Chromatin-remodelling mechanisms in cancer. Mutat. Res., 2008, 658(3), 191-214.
174. Yi, R.; Poy, M. N.; Stoffel, M.; Fuchs, E. A skin microRNA promotes differentiation by repressing 'stemness'. Nature 2008, 452(7184), 225-229. (Pubitemid 351380241)
175. Link, A.; Balaguer; F., Goel, A. Cancer chemoprevention by dietary polyphenols: Promising role for epigenetics. Biochem. Pharmacol., 2010, 80(12), 1771-1792.
176. Balasubramanian, S.; Lee, K.; Adhikary, G.; Gopalakrishnan, R.; Rorke, E. A.; Eckert, R. L., The Bmi-1 polycomb group gene in skin cancer: regulation of function by (-)-epigallocatechin-3-gallate. Nutr Rev 2008, 66 (Suppl 1), S65-S68.
177. Nandakumar, V.; vaid, M.; Katiyar, S.K. (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histone acetylation in human skin cancer cells. Carcinogenesis, 2011, 32(4), 537-544.
178. Vaid, M.; Prasad, R.; Singh, T.; Jones, V.; Katiyar, S.K. Grape seed proanthocyanidins reactivate silenced tumor suppressor genes in human skin cancer cells by targeting epigenetic regulators. Toxicol. Appl. Pharmacol., 2012, 263(1), 122-130.
179. Olaharski, A. J.; Rine, J.; Marshall, B. L.; Babiarz, J.; Zhang, L.; Verdin, E.; Smith, M. T., The flavoring agent dihydrocoumarin reverses epigenetic silencing and inhibits sirtuin deacetylases. PLoS Genet 2005, 1(6), e77.
180. Fang, M.; Chen, D.; Yang, C.S. Dietary polyphenols may affect DNA methylation. J. Nutr., 2007, 137(1), 223S-228S. (Pubitemid 46052885)
181. Li, Y.; Tollefsbol, T.O. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr. Med. Chem., 2010, 17(20), 2141-2151.
182. Li, Y.; Kong, D.; Wang, Z.; Sarkar, F.H. Regulation of microRNAs by Natural Agents: An Emerging Field in Chemoprevention and Chemotherapy Research. Pharm. Res., 2010, 27(6), 1027-1041.
183. Kato, K; Long, N.K.; Makita, H.; Toida, M.; Yamashita, T.; Hatakeyama, D.; Hara, A.; Mori, H.; Shibata, T. Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells. Br. J. Cancer, 2008, 99(4), 647-654.
184. Balasubramanian, S.; Adhikary, G.; Eckert, R.L. The Bmi-1 polycomb protein antagonizes the (2)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival. Carcinogenesis, 2010, 31(3), 496-503.
185. Lee, K.; Adhikary, G.; Balasubramanian, S.; Gopalakrishnan, R.; McCormick, T.; Dimri, G.P.; Eckert, R.L.; Rorke, E.A. Expression of Bmi-1 in epidermis enhances cell survival by altering cell cycle regulatory protein expression and inhibiting apoptosis. J. Invest. Dermatol., 2008, 128(1), 9-17. (Pubitemid 350249374)
186. Asensi, M.; Ortega, A.; Mena, S.; Feddi, F.; Estrela, J.M. Natural polyphenols in cancer therapy. Crit. Rev. Clin. Lab. Sci., 2011, 48(5-6), 197-216.
187. Garg, A.K.; Buchholz, T.A.; Aggarwal, B.B. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid. Redox Signal., 2005, 7(11-12), 1630-1647. (Pubitemid 41767998)
188. Bentires-Alj, M.; Barbu, V.; Fillet, M.; Chariot, A.; Relic, B.; Jacobs, N.; Gielen, J.; Merville, M.P.; Bours, V. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene, 2003, 22(1), 90-97. (Pubitemid 36152887)
189. Quan, F.; Pan, C.; Ma, Q.; Zhang, S.; Yan, L. Reversal effect of resveratrol on multidrug resistance in KBv200 cell line. Biomed. Pharmacother., 2008, 62(9), 622-629.
190. Suttana, W.; Mankhetkorn, S.; Poompimon, W.; Palagani, A.; Zhokhov, S.; Gerlo, S.; Haegeman, G.; Vanden Berghe, W. Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols. Mol. Cancer., 2010, 9, 99-104.
191. Tan, A.C.; Konczak, I.; Sze, D.M.; Ramzan, I. Molecular pathways for cancer chemoprevention by dietary phytochemicals. Nutr. Cancer, 2011, 63(4), 495-505.
192. Cho, M.Y.; Park, S.Y.; Park, S.; Lee, Y.R.; Kwak, M.K.; Kim, J.A. Effects of geranyl-phloroacetophenone on the induction of apoptosis and chemosensitization of adriamycin-resistant MCF-7 human breast cancer cells. Arch. Pharm. Res., 2012, 35(5), 911-919.
193. Babich, H.; Gottesman, R.T.; Liebling, E.J.; Schuck, A.G. Theaflavin-3-gallate and theaflavin-3'-gallate, polyphenols in black tea with prooxidant properties. Basic Clin. Pharmacol. Toxicol., 2008, 103(1), 66-74. (Pubitemid 351874530)
194. Hayeshi, R.; Mutingwende, I.; Mavengere, W.; Masiyanise, V.; Mukanganyama, S. The inhibition of human glutathione S-Transferases activity by plant polyphenolic compounds ellagic acid and curcumin. Food Chem. Toxicol., 2007, 45(2), 286-295. (Pubitemid 44854313)
195. Gatouillat, G.; Balasse, E.; Joseph-Pietras, D.; Morjani, H.; Madoulet, C. Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma. J. Cell. Biochem., 2010, 110(4), 893-902.
196. Bhardwaj, A.; Sethi, G.; Vadhan-Raj, S.; Bueso-Ramos, C.; Takada, Y.; Gaur, U.; Nair, A.S.; Shishodia, S.; Aggarwal, B,B. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through downregulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood, 2007; 109(6), 2293-2302. (Pubitemid 46425866)
197. Prasad, V.S.; Devi P.U.; Rao B.S.; Kamath R. Radiosensitizing effect of plumbagin on mouse melanoma cells grown in vitro, Indian J. Exp. Biol., 1996, 34(9), 857-858. (Pubitemid 26289497)
198. Scarlatti, F.; Sala, G.; Ricci, C.; Maioli, C.; Milani, F.; Minella, M.; Botturi, M.; Ghidoni, R. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett., 2007, 253(1), 124-130. (Pubitemid 46874732)
199. Landis-Piwowar, K.R.; Milacic, V.; Chen, D.; Yang, H.; Zhao, Y.; Chan, T.H.; Yan, B.; Dou, Q.P. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug. Resist. Updat., 2006, 9(6), 263-273. (Pubitemid 46357634)
200. Shen, M.; Chan, T.H.; Dou, Q.P. Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization. Anticancer Agents Med. Chem., 2012, Epub ahead of print, Jan 31.
201. Wu, Y.X.; Fang, X. Apigenin, Chrysin, and Luteolin Selectively Inhibit Chymotrypsin-Like and Trypsin-Like Proteasome Catalytic Activities in Tumor Cells. Planta Med., 2010, 76(2), 128-132.
202. Chen, D.; Frezza, M.; Schmitt, S.; Kanwar, J.; Dou, Q.P. Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives D. Curr. Cancer Drug Targets. 2011, 11(3): 239-253.
203. Yang, H.; Landis-Piwowar, K.R.; Chen, D.; Milacic, V.; Dou, Q.P. Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment. Curr. Protein Pept. Sci., 2008, 9(3), 227-239. (Pubitemid 351997839)
204. Kane, R.C.; Farrell, A.T.; Sridhara, R.; Pazdur, R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Cancer Res., 2006, 12(10), 2955-2960. (Pubitemid 43837337)
205. Nikiforov, M.A.; Riblett, M.; Tang, W.H.; Gratchouck, V.; Zhuang, D.; Fernandez, Y.; Verhaegen, M.; Varambally, S.; Chinnaiyan, A.M.; Jakubowiak, A.J.; Soengas, M.S. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc. Natl. Acad. Sci. U.S.A., 2007, 104(49), 19488-19493.
206. Fernández, Y.; Verhaegen, M.; Miller, T.P.; Rush, J.L.; Steiner, P.; Opipari, A.W.Jr.; Lowe, S.W.; Soengas, M.S. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res., 2005, 65(14), 6294-6304. (Pubitemid 40994415)
207. Brohem, C.A.; Massaro, R.R.; Tiago, M.; Marinho, C.E.; Jasiulionis, M.G.; de Almeida, R.L.; Rivelli, D.P.; Albuquerque, R.C.; de Oliveira, T.F.; de Melo Loureiro, A.P.; Okada, S.; Soengas, M.S.; de Moraes Barros, S.B.; Maria-Engler, S.S. Proteasome inhibition and ROS generation by 4-nerolidylcatechol induces melanoma cell death. Pigment Cell Melanoma Res., 2012, 25(3), 354-369.
208. Zhan, Y.; Jia, G.; Wu, D.; Xu, Y.; Xu, L. Design and Synthesis of a Gossypol Derivative with Improved Antitumor Activities. Arch. Pharm. Chem. Life Sci., 2009, 342(4), 223-229.
209. Dash, R.; Azab, B.; Quinn, B.A.; Shen, X.; Wang, X.Y.; Das, S.K.; Rahmani, M.; Wei, J.; Hedvat, M.; Dent, P.; Dmitriev, I.P.; Curiel, D.T.; Grant, S.; Wu, B.; Stebbins, J.L.; Pellecchia, M.; Reed, J.C.; Sarkar, D.; Fisher, P.B. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc. Natl. Acad. Sci. U.S.A., 2011, 108(21), 8785-8790.
210. Cabello, C.M.; Lamore, S.D.; Bair, W.B.3rd; Qiao, S.; Azimian, S.; Lesson, J.L.; Wondrak, G.T. The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis. Invest. New Drugs, 2012, 30(4), 1289-1301.
211. Landis-Piwowar, K.R.; Wan, S.B.; Wiegand, R.A.; Kuhn, D.J.; Chan, T.H.; Dou, Q.P. Methylation suppresses the proteasome-inhibitory function of green tea polyphenols. J. Cell Physiol., 2007, 213(1), 252-260. (Pubitemid 47378814)
212. Chen, D., Wan, S.B.; Yang, H.; Yuan, J.; Chan, T.H.; Dou, Q.P. EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. Adv. Clin. Chem., 2011, 53, 155-177.
213. Yerlikaya, A.; Okur, E.; Eker, S.; Erin, N. Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line. Mol. Med. Report, 2010, 3(2), 333-339.
214. Liu, F.T.; Agrawal, S.G.; Movasaghi, Z.; Wyatt, P.B.; Rehman, I.U.; Gribben, J.G.; Newland, A.C.; Jia, L. Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood, 2008, 11(9), 3835-3846.
215. Checinska, A.; Soengas, M.S. The gluttonous side of malignant melanoma: basic and clinical implications of macroautophagy. Pigment Cell Melanoma Res., 2011, 24(6), 1116-1132.
216. Chen, N., Debnath, J. Autophagy and tumorigenesis. FEBS Lett., 2010, 584(7), 1427-1435.
217. Amaravadi, R.K.; Lippincott-Schwartz, J.; Yin, X.M.; Weiss, W.A.; Takebe, N.; Timmer, W.; Di Paola, R.S.; Lotze, M.T.; White, E. Principles and current strategies for targeting autophagy for cancer treatment. Clin. Cancer Res., 2011, 17(4), 654-666.
218. Davids, L.M.; Kleemann, B.; Cooper, S.; Kidson, S.H. Melanomas display increased cytoprotection to hypericin-mediated cytotoxicity through the induction of autophagy. Cell Biol. Int., 2009, 33(10), 1065-1072.
219. Psahoulia, F.H.; Moumtzi, S.; Roberts, M.L.; Sasazuki, T.; Shirasawa, S.; Pintzas, A. Quercetin mediates preferential degradation of oncogenic Ras and causes autophagy in Ha-RAS-Transformed human colon cells. Carcinogenesis, 2007, 28(5), 1021-1031. (Pubitemid 47072186)
220. Delmas, D.; Solary, E.; Latruffe, N. Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe. Curr. Med. Chem., 2011, 18(8), 1100-1121.
221. Das, M.; Das, D.K. Resveratrol and cardiovascular health. Mol. Aspects Med., 2010, 31(6), 503-512.
222. Kasten-Pisula, U.; Windhorst, S.; Dahm-Daphi, J.; Mayr, G.; Dikomey, E. Radiosensitization of tumor cell lines by the polyphenol Gossypol results from depressed double-strand break repair and not from enhanced apoptosis. Radiother. Oncol., 2007, 83(3), 296-303. (Pubitemid 46915544)
223. Devi, P.U.; Kamath, R.; Rao, B.S. Radiosensitization of a mouse melanoma by withaferin A: in vivo studies. Indian J. Exp. Biol., 2000, 38(5), 432-437. (Pubitemid 30368821)
224. Katiyar, S.K. Green tea prevents non-melanoma skin cancer by enhancing DNA repair. Arch. Biochem. Biophys., 2011, 508(2): 152-158.
225. Hönigsmann, H. History of phototherapy in dermatology. Photochem. Photobiol. Sci., 2012, Epub ahead of print, Jun 27.
226. Lee, Y.; Baron, E.D. Photodynamic therapy: current evidence and applications in dermatology. Semin. Cutan. Med. Surg., 2011, 30(4), 199-209.
227. Stern, R.S. PUVA follow-up study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J. Am. Acad. Dermatol., 2012, 66(4), 553-562.
228. Archier, E.; Devaux, S.; Castela, E.; Gallini, A.; Aubin, F.; Le Maitre, M.; Aractingi, S.; Bachelez, H.; Cribier, B.; Joly, P.; Jullien, D.; Misery, L.; Paul, C.; Ortonne, J.P.; Richard, M.A. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J. Eur. Acad. Dermatol. Venereol., 2012, Suppl 3, 22-31.
229. Atta, M.; Papanicolaou, N.; Tsirigotis, P. The role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphomas. Transfus. Apher. Sci., 2012, 46(2), 195-202.
230. Ochsner, M. Photophysical and photobiological processes in the photodynamic therapy of tumors. J. Photochem. Photobiol. B., 1997, 39(1), 1-18. (Pubitemid 27285576)
231. Yoshii, H.; Yoshii, Y.; Asai, T.; Furukawa, T.; Takaichi, S.; Fujibayashi, Y. Photo-excitation of carotenoids causes cytotoxicity via singlet oxygen production. Biochem. Biophys. Res. Commun., 2012, 417(1), 640-645.
232. Conforti, F.; Menichini, G.; Zanfini, L.; Tundis, R.; Statti, G.A.; Provenzano, E.; Menichini, F.; Somma, F.; Alfano, C. Evaluation of phototoxic potential of aerial components of the fig tree against human melanoma. Cell. Prolif., 2012, 45(3), 279-285.
233. Menichini, G.; Alfano, C.; Provenzano, E.; Marrelli, M.; Statti, G.A.; Menichini, F.; Conforti, F. Cachrys pungens Jan inhibits human melanoma cell proliferation through photo-induced cytotoxic activity. Cell. Prolif., 2012, 45(1),9-47.
234. Garg, A.D.; Nowis, D.; Golab, J.; Agostinis, P. Photodynamic therapy: illuminating the road from cell death towards anti-Tumor immunity. Apoptosis, 2010, 15(9), 1050-1071.
235. Palumbo, A.; Hauler, F.; Dziunycz, P.; Schwager, K.; Soltermann, A.; Pretto, F.; Alonso, C.; Hofbauer, G.F.; Boyle, R.W.; Neri, D. A chemically modified antibody mediates complete eradication of tumors by selective disruption of tumor blood vessels. Br. J. Cancer, 2011, 104(7), 1106-1115.
236. Kabingu, E.; Oseroff, A.R.; Wilding, G.E.; Gollnick, S.O. Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy. Clin. Cancer Res., 2009, 15(13), 4460-4466.
237. Canti, G.; Lattuada, D.; Nicolin, A.; Taroni, P.; Valentini G., Cubeddu, R. Antitumorimmunity induced by photodynamic therapy with aluminium disulfonated phthalocyanines and laser light, Anti-Cancer Drugs, 1994, 5(4), 443-447. (Pubitemid 24237076)
238. Gollnick, S.O.; Brackett, C.M. Enhancement of anti-Tumor immunity by photodynamic therapy. Immunol. Res., 2009, 46(1-3), 216-226.
239. Korbelik, M. Cancer vaccines generated by photodynamic therapy. Photochem. Photobiol. Sci., 2011, 10(5), 664-669.
240. Ibbotson, S.H. Adverse effects of topical photodynamic therapy. Photodermatol. Photoimmunol. Photomed., 2011, 27(3), 116-130.
241. Morton, C.A.; McKenna, K.E.; Rhodes, L.E. British Association of Dermatologists Therapy Guidelines and Audit Subcommittee and the British Photodermatology Group. Guidelines for topical photodynamic therapy: update. Br. J. Dermatol., 2008, 159(6), 1245-1266.
242. Prado, R.; Francis, S.O.; Mason, M.N.; Wing, G.; Gamble, R.G.; Dellavalle, R. Nonmelanoma skin cancer chemoprevention. Dermatol. Surg., 2011, 37(11), 1566-1578.
243. Allison, R.R.; Sibata, C.H. Oncologic photodynamic therapy photosensitizers: a clinical review. Photodiagnosis Photodyn. Ther., 2010, 7(2), 61-75.